Cannabis And Cancer
With ever-increasing costs of conventional healthcare, and continuing issues with insurance coverage, alternative medicine is growing in popularity. Inasmuch as it is still officially denigrated, cannabis is about as "alternative" as it gets. This, despite no shortage of historic references to cannabis, or its extract marijuana (prepared from the dried and crushed flowers and leaves of the plant) as to its medicinal effects. Chinese Emperors Fu Hsi (2900 BC) and Shen Nung (2700 BC) are said to have touted its healing effects. Some authorities claim that the anointing oil in Exodus 30:22-25 contained cannabis, and that "cane" is a mistranslation from the original Hebrew (1450 BC). Getting more into modern times, marijuana was added to the US Pharmacopeia in 1850, and its use is indicated for an astonishingly diverse litany of illnesses. According to this PDQ Review from the National Cancer Institute, and referring to this illustration, cannabis may lessen the progression of cancer cells. It also alleviates pain, lowers inflammation and decreases anxiety. An oft-cited study from 1996 on mice and rats suggested that cannabinoids (any of various chemical constituents of cannabis) may have a protective effect against the development of hepatic adenoma tumors and hepatocellular carcinoma. The study also noted decreased incidences of benign tumors in other organs (mammary gland, uterus, pituitary, testis, and pancreas). A review article (2006)—appearin...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Authors: Havill J, Smales L PMID: 33032311 [PubMed - in process]
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
More News: Alternative and Complementary Therapies | Anxiety | Asbestosis | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Chemistry | Chemotherapy | Clinical Trials | Complementary Medicine | Drugs & Pharmacology | Food and Drug Administration (FDA) | Health | Hepatic Adenoma | Hepatocellular Carcinoma | HIV AIDS | Insurance | Liver Cancer | Mesothelioma | Pain | Palliative | Palliative Care | Pancreas | Pancreatic Cancer | Pharmaceuticals | Science | Study | Toxicology | Websites